Thomas Seufferlein

List of Publications by Year
in descending order

140	6,607	81839	71651
papers	citations	39 h-index	76 g-index

167	167	167	11347
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Colorectal cancer. Nature Reviews Disease Primers, 2015, 1, 15065.	18.1	1,104
2	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet, The, 2016, 387, 545-557.	6.3	878
3	SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nature Metabolism, 2021, 3, 149-165.	5.1	378
4	Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy, 2016, 48, 939-948.	1.0	257
5	PKM2 promotes tumor angiogenesis by regulating HIF-1Î± through NF-Î²B activation. Molecular Cancer, 2016, 15, 3.	7.9	233
6	Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network. Nature Cell Biology, 2004, 6, 106-112.	4.6	225
7	Protein kinase D: a family affair. FEBS Letters, 2003, 546, 81-86.	1.3	198
8	Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling. Gut, 2017, 66, 473-486.	6.1	174
9	DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut, 2021, 70, 606-617.	6.1	108
10	Regorafenib. Recent Results in Cancer Research, 2018, 211, 45-56.	1.8	100
11	ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Cancer Research, 2017, 77, 5576-5590.	0.4	94
12	Loss of ATM accelerates pancreatic cancer formation and epithelialâ€“mesenchymal transition. Nature Communications, 2015, 6, 7677.	5.8	90
13	Systemic treatment of pancreatic cancer revisited. Seminars in Oncology, 2019, 46, 28-38.	0.8	81
14	The role of pluripotency factors to drive stemness in gastrointestinal cancer. Stem Cell Research, 2016, 16, 349-357.	0.3	76
15	Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms ofÂthe Pancreas. Gastroenterology, 2016, 151, 267-270.	0.6	76
16	Drug Inhibition of SARS-CoV-2 Replication in Human Pluripotent Stem Cellâ€“Derived Intestinal Organoids. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 935-948.	2.3	69
17	Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society. BMC Cancer, 2017, 17, 850.	1.1	68
18	Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer, 2018, 18, 1298.	1.1	63

#	Article	IF	Citations
19	Recruitment of arfaptins to the trans-Golgi network by PI(4)P and their involvement in cargo export. EMBO Journal, 2013, 32, 1717-1729.	3.5	61
20	Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. Cancers, 2016, 8, 81.	1.7	61
21	Single-cell-resolved differentiation of human induced pluripotent stem cells into pancreatic duct-like organoids on a microwell chip. Nature Biomedical Engineering, 2021, 5, 897-913.	11.6	61
22	Role of the Second Cysteine-rich Domain and Pro275 in Protein Kinase D2 Interaction with ADP-Ribosylation Factor 1,Trans-Golgi Network Recruitment, and Protein Transport. Molecular Biology of the Cell, 2010, 21, 1011-1022.	0.9	57
23	A Dynamic Role of TBX3 in the Pluripotency Circuitry. Stem Cell Reports, 2015, 5, 1155-1170.	2.3	57
24	ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. Critical Reviews in Oncology/Hematology, 2018, 122, 179-193.	2.0	57
25	Tumor-associated macrophage-secreted 14-3-3Î¶ signals via AXL to promote pancreatic cancer chemoresistance. Oncogene, 2019, 38, 5469-5485.	2.6	57
26	ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review. Critical Reviews in Oncology/Hematology, 2017, 110, 81-93.	2.0	54
27	Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cells. Cell Stem Cell, 2021, 28, 1105-1124.e19.	5.2	53
28	HSP90 Supports Tumor Growth and Angiogenesis through PRKD2 Protein Stabilization. Cancer Research, 2014, 74, 7125-7136.	0.4	52
29	Population nutrikinetics of green tea extract. PLoS ONE, 2018, 13, e0193074.	1.1	51
30	Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases. Molecular Biology of the Cell, 2014, 25, 324-336.	0.9	49
31	Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut, 2021, 70, 743-760.	6.1	49
32	Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Cancer Treatment Reviews, 2019, 77, 1-10.	3.4	48
33	Pancreatic cancerâ€derived organoids â€“ a disease modeling tool to predict drug response. United European Gastroenterology Journal, 2020, 8, 594-606.	1.6	48
34	Protein Kinase D1, Reduced in Human Pancreatic Tumors, Increases Secretion of Small Extracellular Vesicles From Cancer Cells That Promote Metastasis to Lung in Mice. Gastroenterology, 2020, 159, 1019-1035.e22.	0.6	47
35	Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. European Journal of Cancer, 2014, 50, 1855-1863.	1.3	46
36	A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Theranostics, 2019, 9, 1280-1287.	4.6	45

#	Article	IF	Citations
37	Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline. Endoscopy, 2019, 51, 266-277.	1.0	45
38	3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. European Journal of Cancer, 2017, 79, 41-49.	1.3	43
39	Treatment of pancreatic cancerâ€"neoadjuvant treatment in resectable pancreatic cancer (PDAC). Translational Gastroenterology and Hepatology, 2019, 4, 21-21.	1.5	42
40	Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. Oncotarget, 2018, 9, 2076-2085.	0.8	42
41	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. Oncologist, 2016, 21, 292-300.	1.9	40
42	Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. PLoS ONE, 2017, 12, e0174308.	1.1	40
43	Protein Kinase D2 Assembles a Multiprotein Complex at the Trans-Golgi Network to Regulate Matrix Metalloproteinase Secretion. Journal of Biological Chemistry, 2016, 291, 462-477.	1.6	39
44	Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells. Oncogene, 2005, 24, 1284-1289.	2.6	38
45	Open Surgical versus Minimal Invasive Necrosectomy of the Pancreasâ€"A Retrospective Multicenter Analysis of the German Pancreatitis Study Group. PLoS ONE, 2016, 11, e0163651.	1.1	37
46	Protein Kinase D1 Mediates Anchorage-dependent and -independent Growth of Tumor Cells via the Zinc Finger Transcription Factor Snail1. Journal of Biological Chemistry, 2012, 287, 32367-32380.	1.6	35
47	Systemic Therapy for Metastatic Pancreatic Cancer. Current Treatment Options in Oncology, 2021, 22, 106.	1.3	33
48	Tbx3 fosters pancreatic cancer growth by increased angiogenesis and activin/nodal-dependent induction of stemness. Stem Cell Research, 2016, 17, 367-378.	0.3	27
49	Precision medicine in pancreatic cancer â€" fact or fiction?. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 74-75.	8.2	26
50	A Prospective Feasibility Trial to Challenge Patientâ€"Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Cancers, 2021, 13, 2539.	1.7	26
51	Characterization of cortactin as an in vivo protein kinase D substrate: Interdependence of sites and potentiation by Src. Cellular Signalling, 2009, 21, 253-263.	1.7	24
52	Intermediate filament reorganization dynamically influences cancer cell alignment and migration. Scientific Reports, 2017, 7, 45152.	1.6	24
53	Mutations and variants of ONECUT1 in diabetes. Nature Medicine, 2021, 27, 1928-1940.	15.2	24
54	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. European Journal of Cancer, 2017, 86, 305-317.	1.3	22

#	Article	IF	Citations
55	Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms. JAMA - Journal of the American Medical Association, 2019, 321, 1686.	3.8	22
56	Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Seminars in Cancer Biology, 2022, 84, 242-254.	4.3	22
57	Regorafenib. Recent Results in Cancer Research, 2014, 201, 185-196.	1.8	22
58	Protein kinase D2 regulates chromogranin A secretion in human BON neuroendocrine tumour cells. Cellular Signalling, 2008, 20, 925-934.	1.7	21
59	Protein kinase D2: a versatile player in cancer biology. Oncogene, 2018, 37, 1263-1278.	2.6	20
60	YAP Activation Drives Liver Regeneration after Cholestatic Damage Induced by Rbpj Deletion. International Journal of Molecular Sciences, 2018, 19, 3801.	1.8	20
61	Dosing to rash? â€“ The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. European Journal of Cancer, 2016, 55, 131-139.	1.3	19
62	Different Regulation of Physiological and Tumor Angiogenesis in Zebrafish by Protein Kinase D1 (PKD1). PLoS ONE, 2013, 8, e68033.	1.1	18
63	Green Tea Extract to Prevent Colorectal Adenomas, Results of a Randomized, Placebo-Controlled Clinical Trial. American Journal of Gastroenterology, 2022, 117, 884-894.	0.2	18
64	Comparison of Acoustic Structure Quantification (ASQ), shearwave elastography and histology in patients with diffuse hepatopathies. BMC Medical Imaging, 2015, 15, 58.	1.4	17
65	Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. Cells, 2020, 9, 2110.	1.8	17
66	A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab. Journal of Clinical Medicine, 2021, 10, 1329.	1.0	17
67	Self-Expandable Metal Stents for Persisting Esophageal Variceal Bleeding after Band Ligation or Injection-Therapy: A Retrospective Study. PLoS ONE, 2015, 10, e0126525.	1.1	17
68	STK33 participates to HSP90-supported angiogenic program in hypoxic tumors by regulating HIF-1Î±/VEGF signaling pathway. Oncotarget, 2017, 8, 77474-77488.	0.8	17
69	Radiation therapy in cholangiocellular carcinomas. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 593-602.	1.0	16
70	DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer, 2016, 16, 21.	1.1	16
71	Transcriptional changes and the role of ONECUT1 in hPSC pancreatic differentiation. Communications Biology, 2021, 4, 1298.	2.0	16
72	Cortactin is a scaffolding platform for the E-Cadherin adhesion complex controlled by protein kinase D1 phosphorylation. Journal of Cell Science, 2016, 129, 2416-29.	1.2	15

#	Article	IF	Citations
73	Differential regulation of PKD isoforms in oxidative stress conditions through phosphorylation of a conserved Tyr in the P+1 loop. Scientific Reports, 2017, 7, 887.	1.6	15
74	Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication. Cancers, 2021, 13, 4844.	1.7	15
75	CDKN2A-Mutated Pancreatic Ductal Organoids from Induced Pluripotent Stem Cells to Model a Cancer Predisposition Syndrome. Cancers, 2021, 13, 5139.	1.7	15
76	Mass spectrometryâ€based secretome analysis of nonâ€small cell lung cancer cell lines. Proteomics, 2016, 16, 2801-2814.	1.3	14
77	An Immunological Glance on Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2020, 21, 3345.	1.8	14
78	Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline. Endoscopy, 2019, 51, C1-C1.	1.0	13
79	Differentiation of human pluripotent stem cells into pancreatic duct-like organoids. STAR Protocols, 2021, 2, 100913.	0.5	13
80	Pluripotency Factors on Their Lineage Move. Stem Cells International, 2016, 2016, 1-16.	1.2	12
81	Endogenously Expressed Antigens Bind Mammalian RNA via Cationic Domains that Enhance Priming of Effector CD8ÂT Cells by DNA Vaccination. Molecular Therapy, 2019, 27, 661-672.	3.7	12
82	Small Extracellular Vesicles Propagate the Inflammatory Response After Trauma. Advanced Science, 2021, 8, e2102381.	5.6	12
83	Tumor biology and cancer therapy â€“ an evolving relationship. Cell Communication and Signaling, 2009, 7, 19.	2.7	11
84	Pancreatic Cancer: Progress in Systemic Therapy. Gastrointestinal Tumors, 2014, 1, 167-179.	0.3	11
85	Pancreatic cancer chemoradiotherapy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 617-628.	1.0	11
86	PKD regulates actin polymerization, neutrophil deformability, and transendothelial migration in response to fMLP and trauma. Journal of Leukocyte Biology, 2018, 104, 615-630.	1.5	11
87	MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer CellsIn VitroandIn Vivo. Stem Cells International, 2019, 2019, 1-11.	1.2	11
88	Small Extracellular Vesicles and Metastasisâ€”Blame the Messenger. Cancers, 2021, 13, 4380.	1.7	11
89	Protein Kinase D family kinases. Bioarchitecture, 2014, 4, 111-115.	1.5	10
90	Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. Oncotarget, 2017, 8, 35193-35204.	0.8	10

#	Article	IF	Citations
91	A Fresh Look on T-Box Factor Action in Early Embryogenesis (T-Box Factors in Early Development). Stem Cells and Development, 2015, 24, 1833-1851.	1.1	9
92	Concerted regulation of actin polymerization during constitutive secretion by Cortactin and PKD2. Journal of Cell Science, 2019, 132, .	1.2	9
93	A tumor-specific neoepitope expressed in homologous/self or heterologous/viral antigens induced comparable effector CD8+ T-cell responses by DNA vaccination. Vaccine, 2020, 38, 3711-3719.	1.7	9
94	Genetic Biopsy for Prediction of Surveillance Intervals after Endoscopic Resection of Colonic Polyps: Results of the GENESIS Study. United European Gastroenterology Journal, 2018, 6, 290-299.	1.6	8
95	Perspective on mHealth Concepts to Ensure Usersâ€™ Empowermentâ€“From Adverse Event Tracking for COVID-19 Vaccinations to Oncological Treatment. IEEE Access, 2021, 9, 83863-83875.	2.6	8
96	COVIDâ€19 and digestive health: Implications for prevention, care and the use of COVIDâ€19 vaccines in vulnerable patients. United European Gastroenterology Journal, 2021, 9, 1091-1095.	1.6	8
97	Digestive cancer screening across Europe. United European Gastroenterology Journal, 2022, 10, 435-437.	1.6	8
98	Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications for a role of NF-ÎºB independent mechanisms. Oncogene, 2003, 22, 8786-8796.	2.6	7
99	<scp>IGF</scp>â€1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells. Journal of Cellular and Molecular Medicine, 2015, 19, 948-959.	1.6	7
100	A time frame permissive for Protein Kinase D2 activity to direct angiogenesis in mouse embryonic stem cells. Scientific Reports, 2015, 5, 11742.	1.6	7
101	High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. Pharmacogenomics, 2015, 16, 1605-1619.	0.6	7
102	The armadillo protein p0071 controls KIF3 motor transport. Journal of Cell Science, 2017, 130, 3374-3387.	1.2	7
103	Enteropathogenic Infections: Organoids Go Bacterial. Stem Cells International, 2021, 2021, 1-14.	1.2	7
104	NEONAX: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancerâ€”A phase II study of the AIO Pancreatic Cancer Group.. Journal of Clinical Oncology, 2014, 32, TPS4158-TPS4158.	0.8	7
105	Organoids at the PUB: The Porcine Urinary Bladder Serves as a Pancreatic Niche for Advanced Cancer Modeling. Advanced Healthcare Materials, 2022, 11, e2102345.	3.9	7
106	Trans-sectoral care in patients with colorectal cancer: Protocol ofÂthe randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN). BMC Cancer, 2015, 15, 997.	1.1	6
107	PRKD2: A two-pronged kinase crucial for the tumor-supporting activity of HSP90. Molecular and Cellular Oncology, 2015, 2, e981444.	0.3	6
108	RINT1 Regulates SUMOylation and the DNA Damage Response to Preserve Cellular Homeostasis in Pancreatic Cancer. Cancer Research, 2021, 81, 1758-1774.	0.4	6

#	Article	IF	Citations
109	Patient Empowerment During the COVID-19 Pandemic by Ensuring Safe and Fast Communication of Test Results: Implementation and Performance of a Tracking System. Journal of Medical Internet Research, 2021, 23, e27348.	2.1	6
110	Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomesâ€"An ESDO Report. Cancers, 2017, 9, 59.	1.7	5
111	CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach. Journal of Cancer Research and Clinical Oncology, 2018, 144, 559-569.	1.2	5
112	Organoidomics â€" falling star or new galaxy in pancreatic cancer?. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 586-587.	8.2	5
113	Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis â€“ Better Treatment?. Visceral Medicine, 2019, 35, 259-265.	0.5	5
114	The impact of pharmacogenomics on gastrointestinal cancer therapy. Pharmacogenomics, 2002, 3, 625-633.	0.6	4
115	Barriers and Facilitating Factors for Research Involvement in Cancer Centers. Cancer Control, 2018, 25, 107327481876547.	0.7	4
116	Time trends in dyspepsia and association with H. pylori and work-related stressâ€"An observational study in white collar employees in 1996 and 2015. PLoS ONE, 2018, 13, e0199533.	1.1	4
117	An IKK/NF-Î²B Activation/p53 Deletion Sequence Drives Liver Carcinogenesis and Tumor Differentiation. Cancers, 2019, 11, 1410.	1.7	4
118	The Selective 5-HT1A Agonist SR57746A Protects Intestinal Epithelial Cells and Enteric Glia Cells and Promotes Mucosal Recovery in Experimental Colitis. Inflammatory Bowel Diseases, 2022, 28, 423-433.	0.9	4
119	From Tumorigenesis to Tumor Progression: Signaling Pathways Driving Tumor Invasion and Metastasis. , 2005, , 299-339.		3
120	Systemic treatment of advanced pancreatic cancerâ€"step by step progress. Gut, 2013, 62, 660-661.	6.1	3
121	Chemoradiotherapy, the backbone of radiotherapy in gastrointestinal oncology. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 511-513.	1.0	2
122	Pancreatic Ductal Organoids React Kras Dependent to the Removal of Tumor Suppressive Roadblocks. Stem Cells International, 2019, 2019, 1-8.	1.2	2
123	Nintedanib plus <scp>mFOLFOX6</scp> as secondâ€line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placeboâ€controlled, phase <scp>II TRICCâ€C</scp> study (<scp>AIOâ€KRK</scp>â€0111). International Journal of Cancer, 2021, 148, 1428-1437.	2.3	2
124	Aseptic Liver Abscesses as an Exceptional Finding in Coganâ€™s Syndrome. Hepatology, 2021, 73, 2067-2070.	3.6	2
125	ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumorsâ€"An explorative randomized phase II trial.. Journal of Clinical Oncology, 2015, 33, TPS4150-TPS4150.	0.8	2
126	DOCOX: A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas.. Journal of Clinical Oncology, 2013, 31, 4034-4034.	0.8	2

#	Article	IF	Citations
127	Neonax (AIO-PAK-0313): Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: A phase II study of the AIO Pancreatic Cancer Group.. Journal of Clinical Oncology, 2015, 33, TPS497-TPS497.	0.8	2
128	Functional Genomic Screening in Human Pluripotent Stem Cells Reveals New Roadblocks in Early Pancreatic Endoderm Formation. Cells, 2022, 11, 582.	1.8	2
129	Which EORTC QLQ-C30 and -CR29 scores are relevant for clinicians for therapy planning and decisions?. Coloproctology, 0, , 1.	0.3	1
130	DocOx (AIO-PK0106): A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreasâ€"Final results.. Journal of Clinical Oncology, 2015, 33, 352-352.	0.8	1
131	The MIRACLE trial: A randomized, controlled trial comparing green tea extract versus placebo for the prevention of metachronous colon adenomas in a screening population.. Journal of Clinical Oncology, 2015, 33, TPS786-TPS786.	0.8	1
132	A rare cause of upper GI bleeding and wasting disease. Gut, 2016, 65, 787-787.	6.1	0
133	Novel Concepts in the Management of Colorectal Cancer. Visceral Medicine, 2019, 35, 245-246.	0.5	0
134	Transcutaneous carbon dioxide monitoring as a valid complementary method in acute respiratory failure. European Respiratory Journal, 2020, 56, 2002137.	3.1	0
135	Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity. Oncotarget, 2021, 12, 982-995.	0.8	0
136	DocOx (AIO-PK0106): A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreasâ€"Final results.. Journal of Clinical Oncology, 2015, 33, 4122-4122.	0.8	0
137	The occurrence of mutant KRAS clones in the blood of RAS wild type colorectal cancer patients: Impact of response or failure under anti-EGFR therapy.. Journal of Clinical Oncology, 2016, 34, 600-600.	0.8	0
138	Surveillance after curative resection of pancreatic ductal adenocarcinoma: A multicenter survey in Germany.. Journal of Clinical Oncology, 2016, 34, e15713-e15713.	0.8	0
139	Etiology and Morphology Impact on the Clinical Course of Chronic Pancreatitis. Digestion, 2021, 102, 462-468.	1.2	0
140	Green tea extract to prevent colorectal adenomas in men and women: Results of the MIRACLE trial.. Journal of Clinical Oncology, 2020, 38, 1551-1551.	0.8	0